KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to -$48.9 million.

  • Nektar Therapeutics' Free Cash Flow fell 959.01% to -$48.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$190.4 million, marking a year-over-year decrease of 705.0%. This contributed to the annual value of -$177.2 million for FY2024, which is 842.19% up from last year.
  • Per Nektar Therapeutics' latest filing, its Free Cash Flow stood at -$48.9 million for Q3 2025, which was down 959.01% from -$45.8 million recorded in Q2 2025.
  • Nektar Therapeutics' 5-year Free Cash Flow high stood at -$37.9 million for Q2 2024, and its period low was -$157.4 million during Q4 2021.
  • Its 5-year average for Free Cash Flow is -$65.9 million, with a median of -$51.7 million in 2023.
  • As far as peak fluctuations go, Nektar Therapeutics' Free Cash Flow plummeted by 9066.04% in 2021, and later surged by 6302.26% in 2022.
  • Quarter analysis of 5 years shows Nektar Therapeutics' Free Cash Flow stood at -$157.4 million in 2021, then soared by 63.02% to -$58.2 million in 2022, then grew by 18.78% to -$47.3 million in 2023, then rose by 1.35% to -$46.6 million in 2024, then decreased by 4.78% to -$48.9 million in 2025.
  • Its Free Cash Flow was -$48.9 million in Q3 2025, compared to -$45.8 million in Q2 2025 and -$49.1 million in Q1 2025.